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The magnitude of the problem
Hepatitis B (HBV) and C (HCV) virus infections
represent a major problem in dialysis patients and
renal allograft recipients.
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(i) They cause renal failure due to glomerulone-
phritis, which may recur in the renal transplant
[1].
(ii) Patients with chronic renal failure have
acquired hepatitis virus infection via blood
transfusions, which were necessary to treat
hyporegenerative renal anaemia. With the
advent of recombinant human erythropoietin,
this has now become a minor source of
transmission. However, repetitive invasive
diagnostic and therapeutic interventions still
cause major bleeding episodes in the context of
uraemia.
(iii) HBV and HCV infections are difﬁcult to treat
because of the limited efﬁcacy and a high rate
of side effects of the available drugs.
(iv) No HCV vaccination is available yet.
Prevalence of HBV and HCV infection
The prevalence of HBV and HCV infection in patients
on renal replacement therapy varies considerably
among different areas of the world (Table 1) [2]. It is
usually similar in dialysis patients and renal transplant
recipients, but high compared with the general
population, indicating that infections occur mainly
during the time on dialysis. Two epidemiological
patterns can be observed. First is a geographical
distribution, which reﬂects the disease burden in the
general population. It is higher in the Middle East and
Far East compared with Western countries. Within
Europe, a north–south gradient of increased prev-
alence towards the latter has been reported. Second,
countries with a lower socio-economic status have a
higher prevalence of HBV and HCV infection among
dialysis patients, indicating lower resources for main-
tenance of haemodialysis units, HBV vaccination
programmes and erythropoietin treatment. Repetitive
blood transfusions are the single most important factor
for hepatitis virus transmission, whereas infection
through contaminated haemodialysis equipment
occurs less frequently [3]. Finally, patient to patient
transmission of hepatitis virus with transplanted
organs has been reported [4].
Diagnostic approach
Therapeutic options for HBV and HCV infection
are limited in patients on renal replacement therapy.
Therefore, a great effort should be made towards
early diagnosis in the course of chronic renal
insufﬁciency.
Diagnosis of infection
HBV infection
Patients at risk are screened by detection of HBV
surface antigen (HBsAg) in serum. Positive HBsAg
indicates HBV infection, but it is not equivalent with
active viral replication, which is assessed by qualitative
(HBeAg) or quantitative tests [HBV DNA polymerase
chain reaction (PCR), hybridization]. We suggest the
use of a DNA-based test to assess HBV replication for
two reasons. (a) Guidelines for therapy decisions are
based on these tests. Whether PCR has any advantage
over hybridization is unresolved. Low PCR titres
(<1106 copies/ml) are usually associated with nega-
tive hybridization tests. A beneﬁt of therapy in these
patients has not been established. (b) A negativeHBeAg
test either results from absence of replication or from a
mutation of the virus in the pre-core region, which is
often associated with even higher viral titres [5].
HCV infection
Screening is performed by anti-HCV antibody detec-
tion in serum. Serology is associated with problems of
speciﬁcity and sensitivity in patients on renal replace-
ment therapy. False-positive results may result from
polyclonal B cell stimulation in the context of other
infections (i.e. human immunodeﬁciency virus) or
autoimmune diseases (i.e. systemic lupus erythemato-
sus) [6,7]. This problem has been overcome with the
introduction of newer generation anti-HCV screening
tests [8]. False-negative results are also observed in
dialysis patients. A recent report from Israel indicated
that 9% of seronegative haemodialysis patients had
positive HCV RNA tests using PCR techniques [9].
Table 1. Prevalence of HBV and HCV infection in patients on
renal replacement therapya
Haemodialysis
patients
Renal transplant
recipients
HBV HCV HBV HCV
Europe
Netherlands 2.9–3.4%
Switzerland 1.5% 5% 2.4% 7.2%
Germany 4.6% 7% 3% 13%
Spain 2.8% 19–30% 46%
Italy 4.3% 47–60% 4% 33%
America
USA 2.4% 8.4% 10.3%
Brazil 12–45% 11–26% 27% 40%
Middle/Far East
Israel 18% 12.3%
Syria 49%
Saudi Arabia 68%
India 4–36% 37%
China 30% 15% 50%
Taiwan 22% 34% 31% 39%
Japan 2.1% 27% 21.7%
Africa
Tunisia 53% 42%
aAll data are retrieved from recent publications (<10 years old).
However, the actual prevalence in some of the countries might have
changed due to speciﬁc health care programmes. A list of the
references is available from the authors upon request.
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This ﬁnding profoundly inﬂuences infection contain-
ment programmes in haemodialysis units. We suggest
that all patients with advanced renal insufﬁciency
receive serological HCV screening. In case of a positive
result, it should be followed by HCV RNA PCR to
determine the viral load, which is the basis for
therapeutic decisions. Usually 80–90% of patients
harbour replicating virus, whereas the remaining have
successfully cleared it [10]. All patients entering a renal
replacement programme (dialysis or renal transplanta-
tion) should at least undergo one HCV RNA PCR
test, irrespective of their serological status, since
active viral replication has profound individual and
epidemiological implications.
Assessment of liver disease severity
A number of studies have tried to assess the severity of
liver disease by serological tests in order to avoid liver
biopsy, which has an increased risk of bleeding in
uraemic patients and haemodialysis patients receiving
regular anticoagulation therapy with heparin. The
most promising combination of six markers has been
reported as FibroTest [11], but it remains to be
evaluated in patients on immunosuppressive therapy
or dialysis. We recently compared serum concentra-
tions of transaminases and hyaluronate (a ﬁbrosis
marker) with liver biopsy results in over 40 renal
allograft recipients and found no correlation (Figure 1)
[10]. Therefore, we suggest that a liver biopsy is
performed in all patients with moderate to severe
renal failure and patients on renal replacement
therapy, if they have replicating HBV or HCV infec-
tion with elevated transaminases and if antiviral
therapy is feasible and accepted by the patient in case
of positive histological ﬁndings. In patients with a high
risk of bleeding, prophylaxis with deamino-D-arginine
vasopressin for uraemic platelet dysfunction is recom-
mended [12] and a transjugular biopsy approach
should be evaluated.
HBV and HCV infection harbour the risk of
developing hepatocellular carcinoma. Therefore, and
irrespective of other therapeutic decisions, these
patients should be followed by twice yearly ultrasound
of the liver and alpha-fetoprotein determination.
Therapeutic approach
Therapeutic decisions for HBV and HCV infection
are based on three requirements: (A) demonstration
of viral replication; (B) biochemical evidence of
hepatitis by repeatedly elevated transaminase levels
(>1.5 upper normal value); and (C) liver biopsy
showing either mild inﬂammation and/or ﬁbrosis. A
compilation of therapeutic options in renal patients is
given in Table 2.
Role and risks of interferon therapy
The cornerstone of standard therapies for HBV and
HCV infection is interferon-a. Important side effects
are myelotoxicity and neurological/psychiatric symp-
toms. Therefore, patients with neurological/psychiatric
disorders and patients with haematological disorders
are usually excluded from therapy. In renal patients,
anaemia should be treated with erythropoietin, iron
and vitamin supplements prior to interferon therapy.
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Fig. 1. Correlation of histological and biochemical parameters in 41 renal allograft recipients with chronic HBV or HCV infection. Reprinted
from [10] with permission from the National Kidney Foundation. (A) Correlation of the ﬁbrosis marker hyaluronate with the histological
score of liver ﬁbrosis according to Ishak (scores of 5 and 6 reﬂect focal and diffuse cirrhosis, respectively; 6 is the maximum score).
(B) Correlation of serum glutamate oxaloacetate transaminase (GOT) concentration at the time of biopsy with the histological score of
necroinﬂammatory liver lesions (MHAI; maximum score is 18).
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Patients with autoimmune disorders should be meti-
culously followed for symptoms and signs of their
primary disease, since interferon-a may cause ﬂare-
ups. On the other hand, antiviral therapy is the
standard treatment for virus-induced autoimmunity,
such as HCV-mediated cryoglobulinaemia.
Several reports indicate that interferon-a, as a
non-speciﬁc immunostimulator, causes acute humoral
or cellular rejection of renal allografts in 20–30%
of cases [13–15]. In some cases, rejection could be
successfully treated by standard rejection treatment,
including steroids and anti-T cell antibodies [16].
Based on these ﬁndings we suggest that a therapeutic
strategy without interferon-a should primarily be
chosen in renal transplant patients. If everything
fails, interferon-a may be considered upon informed
consent of the patient regarding the risk of allograft
rejection, necessitating intensiﬁed immunosuppressive
treatment and potential graft loss [17].
Speciﬁc therapeutic options in different
patient groups
HBV infection
The primary goal is prevention. A highly efﬁcient
recombinant vaccine for HBV is available. Since the
response rate in patients with advanced renal failure
and dialysis patients is impaired [18], vaccination
should be performed at an early stage of renal
insufﬁciency. For haemodialysis patients, a special
vaccine at a 4-fold higher dose can be used.
In case of replicating HBV infection with histo-
logical alterations, antiviral therapy should be con-
sidered. In patients with advanced renal failure and in
dialysis patients – especially transplant candidates – a
therapeutic trial with interferon-a should be per-
formed, since it offers the best chance of cure. In
case of treatment failure or serious contraindications,
the antiviral drugs lamivudine and adefovir dipivoxil
may be considered [19]. Whereas lamivudine has been
the standard treatment for years, adefovir dipivoxil
has only recently proven to be effective against
lamivudine-resistant HBV. Combination treatment
has comparable primary response rates, but a lower
rate of therapy failure due to lamivudine resistance
from monotherapy. However, no controlled trials with
adefovir dipivoxil have been performed in patients
with advanced renal insufﬁciency or in renal allograft
recipients. In transplant candidates with contraindica-
tions for interferon-a, the risk of replicating HBV
infection has to be balanced carefully against the risk
of developing lamivudine resistance with the loss of a
treatment option after transplantation.
For patients with a renal allograft we recommend
ﬁrst-line treatment with lamivudine, thus, avoiding
the risk of interferon-induced rejection. A recent
report showed excellent response rates (biochemical:
80–100%; virological: 67–100%) [20]. In case of
treatment failure or development of lamivudine
resistance, a trial with adefovir dipivoxil or a combina-
tion of both antiviral drugs can be performed and
the patient should be followed together with an
experienced hepatologist.
HCV infection
Therapy of HCV infection in renal allograft recipients
is difﬁcult since interferon should be avoided and
ribavirin alone has failed to induce a sustained
virological response or amelioration of liver histology
[21]. Furthermore, our recent report on liver biopsies in
23 renal allograft recipients with chronic HCV infection
showed that none of them had developed cirrhosis after
a mean follow-up of 12 years post-transplantation
[10]. This indicates that part of the liver damage may be
induced by immunological mechanisms rather than
by HCV itself [22] and, hence, may even improve
under immunosuppressive therapy. Therefore, renal
allograft recipients with replicating HCV infection
should not receive therapy, except for patients included
in clinical studies and individual cases with very
aggressive disease [17].
Patients with moderate to severe renal insufﬁciency
are treated according to standard protocols, including
pegylated (PEG-)interferon-a and ribavirin [23].
Table 2. Therapeutic options for HBV and HCV infection in renal patients
Patient with Chronic renal failure Dialysis Renal allograft
HBV infection
Prevention with vaccine Yes (higher dose) Yes (higher dose) Yes
First-line treatment Interferon-a Interferon-a Lamivudine
Second-line treatmenta Lamivudine Lamivudine Adefovir dipivoxil
Adefovir dipivoxil Adefovir dipivoxil Combination of both?
Combination of both? Combination of both?
HCV infection
Prevention with vaccine Not available Not available Not available
First-line treatment PEG-interferonþ ribavirin PEG-interferon±ribavirinb No treatment
Second-line treatmenta ? ? PEG-interferon/ribavirin
Ribavirinþ amantadine?
aIn case of contraindications to interferon or failure of ﬁrst-line treatment. bOnly with monitoring of ribavirin blood levels.
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In dialysis patients, ribavirin should only be given
when blood levels can be monitored, as severe
haemolytic anaemia may develop due to overdosing
[24,25]. Sustained virological response is lower with
interferon-a monotherapy. However, two recent
reports showed a response rate of 40–60% in this
population. All patients that were subsequently trans-
planted remained HCVRNA PCR-negative, indicating
permanent viral clearance [26], and only one developed
recurrent glomerulonephritis [27].
Conclusion
Chronic HBV and HCV infection in patients on renal
replacement therapy represent a major medical and
epidemiological challenge to treating physicians. Due
to the substantial morbidity and mortality associated
with these conditions, special consideration regarding
monitoring and evaluation of therapeutic options is
mandatory. Unfortunately, medical therapy is limited
in these patients, which puts even more emphasis
on prophylactic measures, such as early vaccination
against HBV, and prevention of viral transmission
during time on dialysis.
Conﬂict of interest statement. None declared.
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